Home Technology Seminars

Technology Seminar (10 Oct 2013)

Print

 

Technology Seminar

TALEN and CRISPR/Cas9 Systems as
Advanced Toolbox for Precise Genome
Editing and Gene Regulation

By

Dr Jian-Ping Yang

Staff Scientist
Life Technologies


10 October 2013 (Thu)

3:00 – 4:00pm



Seminar Room 7-03, 7/F,

The Hong Kong Jockey Club Building for Interdisciplinary Research

5 Sassoon Road, Pokfulam, Hong Kong

 

Abstract:

Engineered transcriptional activator-like effector nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) have emerged as attractive tools for inducing genetic modifications in various organisms and cell types. We will present some showcases on utility of TALE-mediated transcriptional activators, repressors on modulation of endogenous genes which may eventually lead to the development of synthetic cellular circuits and efficient tools for cellular reprogramming specially in human cells. Double strand DNA breaks at specific loci generated by TALENs and CRISPR/Cas9 enable to create disease models and reporter cell lines through efficiently gene knock-in through homologous recombination with a donor DNA, or gene knock-out through error-prone non-homologous end joining. We will present the newly developed tools by Life Technologies Corp to facilities the application of TALN and CRISPR in human cells.

 
 

Brief CV of the Speaker:

Jian-Ping Yang is a staff scientist in the Synthetic Biology Group at Life Technologies. He earned his PhD degree in Molecular Genetics in the laboratory of Dr. Okamoto Takashi from Nagoya City University Medical School, Japan, where he focused his studies on signal pathways of NF-kB involved in HIV, inflammatory diseases, and cancer. He did postdoctoral work in the laboratory of Dr. Flossie Wong-Staal at the University of California, San Diego working on regulation pathways of infectious virus replication. Since then, he was employed at Immusol as a research scientist focusing on assay development, drug and target identification for infectious diseases, neurodegenerative diseases, and cancer. He joined Life Technologies/Invitrogen in 2007 and has been instrumental in developing lentiviral vectors, baculovirus vectors, cell-free expression systems, and GeneArt Seamless cloning. He currently focuses his efforts on genome editing and cell engineering technologies including TALE and CRISPR, as well as other supporting technologies.

 

ALL ARE WELCOME


Co-organized with Life Technologies Life-Tech Logo
Refreshment to be served
For enquiries, please call 2831-5500 or write to This e-mail address is being protected from spambots. You need JavaScript enabled to view it